

TABLE OF CONTENTS

HEADS OF AGENCIES – CMDH	1
HEADS OF AGENCIES – PAEDIATRIC REGULATION	1
EUROPEAN MEDICINES AGENCY (EMA)	1
NOTICE TO APPLICANTS	5
BFARM - PHARMAKOVIGILANZ (SPECIFIC FOR GERMANY)	5
BFARM – MEDIZINPRODUKTE (SPECIFIC FOR GERMANY)	6
PEI - VIGILANZ (SPECIFIC FOR GERMANY)	6
PHARMEUROPA TEXTS FOR COMMENT	6

HEADS OF AGENCIES – CMDh

No updates since August 4th, 2026.

HEADS OF AGENCIES – PAEDIATRIC REGULATION

Article 45 work-sharing: [click here](#)

EUROPEAN MEDICINES AGENCY (EMA)

Date	Content	Status
11/09/2026	Medicine: Aybintio bevacizumab	Updated
11/09/2026	Medicine: Saphnelo anifrolumab	Updated
11/09/2026	Medicine: Vyloy zolbetuximab	Updated
11/09/2026	Medicine: Repaglinide Accord repaglinide	Updated
11/09/2026	Medicine: Bilprevda denosumab	Updated
11/09/2026	Medicine: Emgality galcanezumab	Updated
11/09/2026	Medicine: Lynkuet elinzanetant	Updated
11/09/2026	Medicine: Cirbloc porcine circovirus vaccine (inactivated)	New
11/09/2026	Medicine: AviGate S. Typhimurium Salmonella enterica, subsp. enterica, serovar Typhimurium, strain Nal2/Rif9/Rtt, Live	New
11/09/2026	News: Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 8-10 September 2026	New
11/09/2026	Post-authorisation: Firocoxib CP-Pharma - opinion on variation to marketing authorisation firocoxib	New

Date	Content	Status
11/09/2026	Post-authorisation: Vectormune HVT-AIV - opinion on variation to marketing authorisation Avian influenza vaccine	New
11/09/2026	Post-authorisation: Felpreva - opinion on variation to marketing authorisation emodepside; praziquantel; tigolaner	New
11/09/2026	Post-authorisation: Vectra 3D - opinion on variation to marketing authorisation dinotefuran, permethrin, and pyriproxyfen	New
11/09/2026	Page: ICH M12 on drug interaction studies - Scientific guideline	Updated
11/09/2026	Document: Draft guideline on the investigation of interactions in the gastrointestinal tract	New
10/09/2026	Event: HMA / EMA multistakeholder AI and Data forum: Build trustworthy AI on strong data foundations	Updated
10/09/2026	Referral: Veterinary medicinal products containing amoxicillin - referral amoxicillin	Updated
10/09/2026	Medicine: Xeljanz tofacitinib	Updated
10/09/2026	Medicine: Uzpruvo ustekinumab	Updated
10/09/2026	Medicine: Zoledronic acid Mylan zoledronic acid	Updated
10/09/2026	Medicine: Tagrisso osimertinib	Updated
10/09/2026	Medicine: Moventig naloxegol	Updated
10/09/2026	Event: First European Medicines Agency (EMA) - International Society for Cell and Gene Therapy (ISCT) bilateral meeting	New
10/09/2026	Event: Fifth European Medicines Agency (EMA) - Vaccines Europe bilateral meeting	New
10/09/2026	Event: Product Management Service (PMS) public API beta release - Technical overview and live demo	Updated
10/09/2026	Page: Clinical investigation of medicinal products for treatment of migraine - Scientific guideline	Updated
10/09/2026	Document: Draft guideline on clinical investigation of medicinal products for the treatment of migraine and cluster headache - Revision 2	New
09/09/2026	PSUSA: PSUSA/00000405/202601 - periodic safety update report single assessment bezafibrate	New
09/09/2026	Medicine: Amvuttra vutrisiran	Updated
09/09/2026	Page: Expert panel support for orphan medical devices	Updated
09/09/2026	Document: Orphan medical devices regular process: 2027 timetable	New

Date	Content	Status
09/09/2026	Page: Scientific advice for high-risk medical devices	Updated
09/09/2026	Medicine: Perjeta pertuzumab	Updated
09/09/2026	Document: Advice to medical device manufacturers - 2027 Timetable	New
09/09/2026	Medicine: Zilbrysq zilucoplan	Updated
09/09/2026	Medicine: Zercepac trastuzumab	Updated
09/09/2026	Medicine: Colchicine Agepha Pharma colchicine	Updated
09/09/2026	Event: EMA Biotech Hub and Technology Transfer Offices (TTOs) engagement workshop	New
09/09/2026	Document: Agenda of the PRAC meeting 31 August - 3 September 2026	Updated
09/09/2026	Document: Electronic submission of Article 57(2) data: questions and answers	Updated
09/09/2026	Document: Chapter 3.II: XEVPRM detailed user guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA	Updated
09/09/2026	Document: QRD veterinary Appendix I - Adverse event (PhV) MSs reporting details	Updated
09/09/2026	Event: 2026 annual open meeting of the European Network of Paediatric Research at EMA (EnprEMA)	New
09/09/2026	Document: Applications for new human medicines under evaluation: September 2026	New
09/09/2026	Shortage: Eskazole / Zentel albendazole	New
09/09/2026	Shortage: Natpar parathyroid hormone	Updated
09/09/2026	Medicine: Qezzaqar catequentinib	Updated
09/09/2026	Page: Good pharmacovigilance practices (GVP)	Updated
09/09/2026	Document: Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, last updated with revision 2 of Module III on pharmacovigilance inspections	New
09/09/2026	Document: Guideline on good pharmacovigilance practices: Module III - Pharmacovigilance inspections (Rev. 2) with tracked changes	New
09/09/2026	Document: Guideline on good pharmacovigilance practices: Module III - Pharmacovigilance inspections (Rev. 2)	New
09/09/2026	Document: Agenda of the CAT meeting 9-11 September 2026	New

Date	Content	Status
08/09/2026	Medicine: Benlysta belimumab	Updated
08/09/2026	Medicine: Rinvoq upadacitinib	Updated
08/09/2026	Medicine: Sivextro tedizolid phosphate	Updated
08/09/2026	Medicine: Suliqua insulin glargine; lixisenatide	Updated
08/09/2026	Medicine: Lucentis ranibizumab	Updated
08/09/2026	Medicine: Bexsero meningococcal group B Vaccine (rDNA, component, adsorbed)	Updated
08/09/2026	Medicine: Vislyfa ranibizumab	Updated
08/09/2026	Medicine: Lupkynis voclosporin	Updated
08/09/2026	Medicine: Kavigale sipavibart	Updated
08/09/2026	Medicine: Rezolsta darunavir; cobicistat	Updated
08/09/2026	PSUSA: PSUSA/00003159/202512 - periodic safety update report single assessment antithrombin III	New
08/09/2026	Document: Agenda of the CVMP meeting 8-10 September 2026	New
08/09/2026	PSUSA: PSUSA/00010710/202601 - periodic safety update report single assessment alitretinoin (oral use)	New
08/09/2026	Medicine: Olumiant baricitinib	Updated
08/09/2026	Document: Member states contact points for translations review	Updated
08/09/2026	Medicine: Gardasil 9 human papillomavirus 9-valent vaccine (recombinant, adsorbed)	Updated
07/09/2026	Event: EMA/FVE information session for veterinary students: the importance of pharmacovigilance	New
07/09/2026	Medicine: Xolremdi mavoxifafor	Updated
07/09/2026	Document: Co-ordinating good manufacturing practice (GMP) inspections for centrally authorised products	Updated
07/09/2026	Medicine: Fymkina ustekinumab	Updated
07/09/2026	Document: Agenda - PDCO agenda of the 8-11 September 2026 meeting	New
07/09/2026	Medicine: Arava leflunomide	Updated
07/09/2026	Medicine: Nordimet methotrexate	Updated
07/09/2026	Medicine: Jylamvo methotrexate	Updated

Date	Content	Status
07/09/2026	Document: Agenda of the COMP Meeting 8-10 September 2026	New
07/09/2026	PSUSA: PSUSA/00000560/202601 - periodic safety update report single assessment carboprost	New
07/09/2026	Event: EMA Methodology Working Party interested parties meeting 2026	New
07/09/2026	PSUSA: PSUSA/00000164/202601 - periodic safety update report single assessment aminophylline	New
07/09/2026	Page: QRD guidance on the use of adopted abbreviations and pictograms on the packaging of veterinary medicinal products authorised via the centralised (CP), mutual recognition (MRP), decentralised (DCP), subsequent recognition (SRP) and national procedures	Updated
07/09/2026	Document: Guidance on the revised pre-submission interactions model	Updated

NOTICE TO APPLICANTS

No updates since June 24th, 2026.

BFARM - PHARMAKOVIGILANZ (SPECIFIC FOR GERMANY)

Date	Title
08.09.2026	Vorläufige Tagesordnung der 99. Routinesitzung am 28. September 2026 Die 99. Routinesitzung nach § 63 AMG wird am 28. September 2026 ab 10:00 Uhr als Videokonferenz stattfinden.
07.09.2026	Umsetzung des Durchführungsbeschlusses der Europäischen Kommission vom 20.08.2026 zum PSUR Single Assessment betreffend die Zulassungen für Humanarzneimittel mit dem Wirkstoff Methotrexat Das BfArM veröffentlicht den Umsetzungsbescheid für den Wirkstoff Methotrexat infolge des Europäischen PSUR Single Assessment Verfahrens nach Artikel 107d) bis g) der Richtlinie 2001/83/EG.
07.09.2026	Umsetzung des einstimmigen Beschlusses der Koordinierungsgruppe vom 25.06.2026 betreffend die Zulassungen für Humanarzneimittel mit der Wirkstoffkombination Ramipril/Bisoprolol Das BfArM veröffentlicht den Umsetzungsbescheid für die Wirkstoffkombination Ramipril/Bisoprolol infolge des Europäischen PSUR Single Assessment Verfahrens nach Artikel 107d) bis g) der Richtlinie 2001/83/EG

BFARM – MEDIZINPRODUKTE (SPECIFIC FOR GERMANY)

Date	Title
08.09.2026	Vorläufige Tagesordnung der 99. Routinesitzung am 28. September 2026 Die 99. Routinesitzung nach § 63 AMG wird am 28. September 2026 ab 10:00 Uhr als Videokonferenz stattfinden.
08.09.2026	HIIS-VZ nach § 374a SGB V Mit dem in Kraft treten von § 374a SGB V stehen Hersteller von Hilfsmitteln und Implantaten gemäß Kabinettsentwurf für ein Gesetz für Daten und digitale Innovation im Gesundheitswesen (GeDIG) ab dem 01.01.2028 in der Verantwortung, interoperable Schnittstellen anzubieten, damit erhobene Gesundheitsdaten an eine DiGA übermittelt werden können.

PEI - VIGILANZ (SPECIFIC FOR GERMANY)

No updates since August 3rd, 2026.

PHARMEUROPA TEXTS FOR COMMENT

Information on Pharmedeuropa updates will be presented quarterly.

Trotz regelmäßiger Aktualisierung und sorgfältiger Überwachung der Veröffentlichungen können wir keine Haftung oder Garantie für die Aktualität, Richtigkeit und Vollständigkeit der hier bereitgestellten Informationen übernehmen. Dieser Newsletter enthält Links zu anderen Websites. Trotz sorgfältiger inhaltlicher Kontrolle übernehmen wir keine Haftung für die Inhalte externer Links. Für den Inhalt der verlinkten Seiten sind ausschließlich deren Betreiber verantwortlich.

Despite regular updating and careful monitoring of the publications, we cannot take any responsibility or guarantee for the topicality, correctness and completeness of the information provided here. This Newsletter contains links to other websites. Despite careful control of the content we would like to point out that we are not liable for the contents of external web links. The editors of the respective websites are fully responsible for their contents.